• Roche has launched two new, real-time PCR tests to detect cyclospora, a diarrhea-causing infection, to help meet diverse needs of laboratories.
• The new tests expand the Roche cyclospora portfolio, providing laboratories with more flexible choices.
• Cyclospora tests are another example of Roche's leadership in infectious disease testing and long-standing commitment to improving public health.

INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- As a cyclospora outbreak continues to spread throughout the United States,1,2 Roche ((SIX: RO, ROG, OTCQX:RHHBY), in collaboration with subsidiary TIB MOLBIOL, announces the availability of two new flexible and cost-effective research PCR testing options for labs to address the public health impact of the Cyclospora cayetanensis parasite.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.